De Optimal studie:
Optimaliseren van Everolimus behandeling door het splitsen van innamemomenten.

1.Age >18 years;

2.Able and willing to give written informed consent;

3.Able and willing to undergo blood sampling for PK analysis;

4.Histopathologically confirmed cancer for which everolimus is considered standard of care, who will start with or are already receiving everolimus therapy (breast cancer patients will also receive exemestane (in accordance with the summary of product characteristics), other patients will receive everolimus monotherapy).

5.Minimal acceptable safety laboratory values
a.ANC of > 1.5 x 10^9 /L

b.Platelet count of > 100 x 10^9 /L

c.Hepatic function as defined by serum bilirubin ¡Ü 1.5 x ULN, ASAT and ALAT ¡Ü2.5 x ULN
d.Renal function as defined by serum creatinine ¡Ü1.5 x ULN or creatinine clearance >50 mL/min (by Cockcroft-
Gault formula);

1.Woman who are pregnant or breast feeding;

2.Known hypersensitivity to any of the study drugs or excipients;

3.Unable or unwilling to undergo pharmacokinetic sampling;

4.Use of any concomitant medication (including OTC and herbal medication) which may induce or inhibit function
of CYP3A4, including but not limited to efavirenz, etravirine, nevirapine, rifampicine, boceprevir, claritromycine,
elvitegravir, erytromycine, fluconazol, itraconazol, ketoconazol, posaconazol, telaprevir, verapamil, cyclosporine,
voriconazol, dexamethason, St John¡'s Wort and grapefruit juice;

5.Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion
of the investigator would impair study compliance;

6.Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory
finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
or puts the patient at high risk for treatment-related complications;

7.Legal incapacity;
8.CT or other tumour response evaluation planned during the 4 weeks of the trial.